13
4
51
$10M$50M
51$10M$50M
64$10M$50MIconOVir Bio uses 8 technology products and services including QuickBooks, WordPress, MySQL, and more. Explore IconOVir Bio's tech stack below.
| IconOVir Bio Email Formats | Percentage |
| First.Last@iconovir.com | 71% |
| FLast@iconovir.com | 15% |
| Last@iconovir.com | 8% |
| First@iconovir.com | 6% |
Biotechnology ResearchCalifornia, United States11-50 Employees
IconOVir Bio is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer. Our proprietary oncolytic virus platform is based on technology developed by scientific founder Clodagh O’Shea, Ph.D., of the Salk Institute. It is designed to address key limitations of first- and second-generation oncolytic viruses.
Company Overview
Media & News
Funding & FinancialsIconOVir Bio has raised a total of $77M of funding over 1 rounds. Their latest funding round was raised on Jan 05, 2021 in the amount of $77M.
IconOVir Bio's revenue is in the range of $10M
Funding & FinancialsIconOVir Bio has raised a total of $77M of funding over 1 rounds. Their latest funding round was raised on Jan 05, 2021 in the amount of $77M.
IconOVir Bio's revenue is in the range of $10M
1-888-653-2347 
support@leadiq.com